Reference
·Supporting source
Foreign-pharma Thailand clinical-trial spend (2025-2027)
USD 180-340M (cumulative)
AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly Thailand offices anchor approximately USD 180-340 million of cumulative clinical-trial spend across 2025-2027, increasingly structured around AI-stratified cohorts that Thai academic medical centres (Siriraj, Chulalongkorn Hospital, Ramathibodi) can recruit and characterise faster than regional comparators. AstraZeneca and Roche lead the oncology cohort flow; Pfizer, Novartis, and Eli Lilly metabolic and neuro programmes enter the pool through 2026-2027 expansion phases. AI-CRO billing rates at Siriraj run USD 85-180 per stratified patient at 2026 reference rates versus USD 320-540 per patient internal-team workloads on equivalent tasks.
Figure in context
AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly Thailand offices anchor approximately USD 180-340 million of cumulative clinical-trial spend across 2025-2027, increasingly structured around AI-stratified cohorts that Thai academic medical centres (Siriraj, Chulalongkorn Hospital, Ramathibodi) can recruit and characterise faster than regional comparators. AstraZeneca and Roche lead the oncology cohort flow; Pfizer, Novartis, and Eli Lilly metabolic and neuro programmes enter the pool through 2026-2027 expansion phases. AI-CRO billing rates at Siriraj run USD 85-180 per stratified patient at 2026 reference rates versus USD 320-540 per patient internal-team workloads on equivalent tasks.
AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly Thailand offices anchor approximately USD 180-340 million of cumulative clinical-trial spend across 2025-2027, increasingly structured around AI-stratified cohorts that Thai academic medical centres (Siriraj, Chulalongkorn Hospital, Ramathibodi) can recruit and characterise faster than regional comparators. AstraZeneca and Roche lead the oncology cohort flow; Pfizer, Novartis, and Eli Lilly metabolic and neuro programmes enter the pool through 2026-2027 expansion phases. AI-CRO billing rates at Siriraj run USD 85-180 per stratified patient at 2026 reference rates versus USD 320-540 per patient internal-team workloads on equivalent tasks.
Time scope
2025-2027 cumulative
Source basis
Supporting source
Interpretation notes
What this tells you
AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly Thailand offices anchor approximately USD 180-340 million of cumulative clinical-trial spend across 2025-2027, increasingly structured around AI-stratified cohorts that Thai academic medical centres (Siriraj, Chulalongkorn Hospital, Ramathibodi) can recruit and characterise faster than regional comparators. AstraZeneca and Roche lead the oncology cohort flow; Pfizer, Novartis, and Eli Lilly metabolic and neuro programmes enter the pool through 2026-2027 expansion phases. AI-CRO billing rates at Siriraj run USD 85-180 per stratified patient at 2026 reference rates versus USD 320-540 per patient internal-team workloads on equivalent tasks.
What not to do with it
Cumulative USD spend across AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly Thailand offices over 2025-2027. Excludes upstream AI drug discovery offshoring spend captured separately under the THB 14-24B 2027 pool.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Thailand AI drug discovery cost-per-validated-target (2026)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.